From Cognitive MR-Targeted Fusion Prostate Biopsy to Radical Prostatectomy: Incidence and Predictors of Gleason Grade Group Upgrading in a Chinese Cohort

• Published in: BioMed research international Vol. 2022; pp. 1 - 5
• Main Authors: Yan, Huaqing, Wu, Yiming, Cui, Xiaobo, Zheng, Sinian, Zhang, Peng, Li, Rubing
• Format: Journal Article
• Language: English
• Published: New York Hindawi 17-08-2022; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Biopsy; Cancer surgery; Cancer therapies; Care and treatment; Cognitive ability; Diagnosis; Lymphatic system; Magnetic resonance imaging; Methods; Nomograms; Pathology; Patients; Physicians; Prostate cancer; Prostatectomy; Regression analysis; Regression models; Statistical analysis; Surgery; Ultrasonic imaging; Upgrading; Urological surgery; China
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2022/7944342

Purpose. To access the incidence and predictors of Gleason grade group upgrading from cognitive MR-targeted fusion prostate biopsy to radical prostatectomy in a Chinese cohort. Materials and Methods. We included 199 patients in our institution between January 2016 and June 2021. Multivariable logistic regression model and nomograms were utilized to analyze the collected data. Results. The concordance rate of biopsy Gleason grade group and radical prostatectomy was 50.3% (100 in 199). Upgrading occurred in 80 (40.2%) patients and 37 (68.5%) patients have an upgrading Gleason grade group when the biopsy Gleason grade group was 1. Multivariable logistic regression models were established to analyze the incidence and predictors of Gleason grade group upgrading from cognitive MR-targeted fusion prostate biopsy to radical prostatectomy. Biopsy Gleason grade group, prostate volume, and patient year were confirmed to be individual predictors of upgrading. Based on the logistic regression models, nomograms for predicting probability of prostate Gleason grade group upgrading were generated. Conclusions. We established a logistic regression model to predict the accuracy of prostate biopsy GG and provide the probability of upgrading. Clinicians should be more cautious when deciding the treatment strategy especially for prostate cancer biopsy GG1 patients. Future studies should expand the sample size and include more variables to improve the accuracy of predicting upgrading and prostate cancer early screening program is urgently needed in our city in China.